Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
SUNY Upstate Medical University · AstraZeneca (Japan) · +6 more institutions
Abstract
BACKGROUND Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose. METHODS In this trial conducted in both northern and southern hemispheres, we evaluated nirsevimab for the prevention of RSV-associated lower respiratory tract infection in healthy infants who had been born preterm (29 weeks 0 days to 34 weeks 6 days of gestation). We randomly assigned the infants in a 2:1 ratio to receive nirsevimab, at a dose of 50 mg in a single…
Citation impact
- FWCI
- 51.16
- Percentile
- 100%
- References
- 32
Authors
12- MPM. Pamela GriffinCorresponding
SUNY Upstate Medical University, AstraZeneca (Japan), Respiratory and Meningeal Pathogens Research Unit
- YYYuan Yuan
SUNY Upstate Medical University, AstraZeneca (Japan), Respiratory and Meningeal Pathogens Research Unit
- TTTherese Takas
SUNY Upstate Medical University, AstraZeneca (Japan), Respiratory and Meningeal Pathogens Research Unit
- JBJoseph B. Domachowske
SUNY Upstate Medical University, Respiratory and Meningeal Pathogens Research Unit
- SAShabir A. Madhi
University of the Witwatersrand, SUNY Upstate Medical University, Respiratory and Meningeal Pathogens Research Unit, Medical Research Council
Topics & keywords
- Medicine
- Respiratory system
- Virus
- Lower respiratory tract infection
- Respiratory tract
- Respiratory tract infections
- Virology
- Monoclonal antibody
- Good health and well-being